Verified publication
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study
A five-hospital cohort study comparing 306 thymosin alpha-1 recipients with 1,976 non-recipients during early COVID-19 care.
Indexed abstract extractedQuality: ModerateModerate confidence
Study metadata
- Journal
- Frontiers in Immunology
- Publication year
- 2021
- Study type
- Human observational study
- Species
- Human
- Evidence grade
- Grade B
- Extraction depth
- Indexed abstract extracted
- Study quality
- Moderate
- Confidence
- Moderate confidence
- Sample size
- 2282
Structured extraction
- Population
- Human participants; population details require article-level extraction.
- Intervention
- Exposure or intervention details require abstract or full-text extraction before use.
- Comparator
- Not stated or not fully extracted from the indexed abstract.
- Duration
- Not stated or not fully extracted from the indexed abstract.
- Primary endpoint
- Primary outcome or association endpoint not fully extracted.
- Secondary endpoints
- No secondary endpoints extracted.
- Funding source
- Not stated in the indexed abstract.
Findings and extraction notes
- After adjustment, thymosin alpha-1 use was associated with a higher non-recovery rate in this cohort.
Limitations
- Treatment was not randomized and confounding by disease severity remains possible.
- The result is specific to the cohort, timing, and COVID-19 treatment context.